RxDoctor Payments Data

Alissa Gabel, NP

Family · New Brunswick, NJNPI 1306397146

Payments from drug & device makers

$4,602in general payments, 2019–2025

Across 27 payments — averaging $170.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Pfizer$683
  • Janssen Scientific Affairs, LLC$395
  • Seagen Inc.$213
  • Incyte Corporation$130
  • Legend Biotech USA Inc.$79
  • plus $37 from 2 others

What the payments were for

  • Consulting fees$2,86062%
  • Travel & lodging$53312%
  • Food & beverage$93220%
  • Education$2776%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,602 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$40,192
Medicare patients
82
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide123$2,750,040
RevlimidLenalidomide85$1,461,078
Lenalidomide83$1,163,187
JakafiRuxolitinib Phosphate16$272,152
EliquisApixaban45$34,076
XareltoRivaroxaban15$14,022
Acyclovir233$3,151
Fentanyl15$1,368
Gabapentin72$1,093
ValacyclovirValacyclovir Hcl12$617
Ondansetron Hcl39$614
Fluconazole14$458
Pantoprazole Sodium60$458
Prochlorperazine Maleate37$456
Potassium Chloride37$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$130$272,15216 claims
PfizerEliquis$683$34,07645 claims
Johnson & JohnsonXarelto$3,066$14,02215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →